News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Eli Lilly and Company Seeks Approval for Cymbalta in Fibromyalgia
August 21, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BOSTON, Aug 21 (Reuters) - Eli Lilly and Co. (LLY.N: Quote, Profile, Research) said on Tuesday it has filed for U.S. approval to sell its antidepressant Cymbalta as a treatment for the pain condition fibromyalgia.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Eli Lilly and Company
MORE ON THIS TOPIC
Insights
Lean Derisking: Smart Ways to Cross Drug Development’s “Valley of Death”
April 6, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Layoffs
Layoffs at Novo’s Ex-Catalent Site Despite Signs of Turnaround, Continued Investment
April 1, 2026
·
2 min read
·
Nick Paul Taylor
Approvals
Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry
April 1, 2026
·
3 min read
·
Heather McKenzie
Podcast
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
April 1, 2026
·
1 min read
·
Heather McKenzie
